News Related to Transthyretin Amyloidosis With Cardiomyopathy

Related coverage linked through entity extraction aliases.

FDA Lifts Clinical Hold on Intellia's ATTR Cardiomyopathy Trial

Mar 02, 2026

The FDA removed the clinical hold on Intellia Therapeutics' Phase 3 trial of nexiguran ziclumeran for transthyretin amyloidosis with cardiomyopathy. The hold was imposed in October following liver safety concerns in one patient.

FDA Lifts Clinical Hold on Intellia's MAGNITUDE-2 Trial for ATTRv-PN

Feb 28, 2026

The FDA removed the clinical hold on Intellia Therapeutics' MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran for ATTRv-PN, allowing patient enrollment and dosing to resume with enhanced safety monitoring.